on Mainz BioMed N.V.
Mainz Biomed to Showcase Colorectal Cancer Screening Advances
Mainz Biomed N.V. will participate in the WEO CRC Screening Committee Meeting on October 3, 2025, in Berlin. The molecular genetics diagnostics company specializes in early cancer detection. Dr. Lena Krammes, a Senior Scientist at Mainz Biomed, will present research on RNA-based diagnostics at this global event.
The company's findings are part of the "Evaluation of New Tests" session. Key results from their eAArly DETECT study include 97% sensitivity and specificity for colorectal cancer detection. Additionally, they report 82% sensitivity for advanced adenomas and a 100% detection rate for adenomas with high-grade dysplasia.
Mainz Biomed's efforts support global colorectal cancer screening advancements. CEO Guido Baechler emphasizes the importance of their contributions to developing effective screening tools. The company continues to drive innovation in early cancer detection and prevention.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Mainz BioMed N.V. news